Better Diabetes Control, Quality - Educate to Achieve Compliance.

NCT ID: NCT01728714

Last Updated: 2023-10-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

227 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-05-19

Study Completion Date

2018-12-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective study to evaluate the impact of an educational programme about diabetes, comparing to normal clinical practice, on treatment compliance and disease control of people with type 2 diabetes followed in the primary care units in Portugal

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prospective study to evaluate the impact of an educational programme about diabetes focusing on treatment compliance, exercise and nutrition, comparing to normal clinical practice, on treatment compliance and disease control of people with type 2 diabetes followed in the primary care units in Portugal.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adults over 18 years old

Adults over 18 years old, with type 2 diabetes, HbA1c \<= 8,5%, treated with oral antidiabetics at least for 6 months submitted to an educational programme during 1 year

No interventions assigned to this group

Adults with HbA1c <= 8,5%

Adults over 18 years old, with type 2 diabetes, HbA1c \<= 8,5%, treated with oral antidiabetics at least for 6 months followed according to normal clinical practice during 1 year

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals with type 2 diabetes
* HbA1c \<= 8,5%
* Treated with oral antidiabetics for at least 6 months

Exclusion Criteria

\- Treatment with insulin
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cláudia Antão

Role: PRINCIPAL_INVESTIGATOR

Research Site 01

Pedro Carriço

Role: PRINCIPAL_INVESTIGATOR

Research site 02

Carla Gouveia

Role: PRINCIPAL_INVESTIGATOR

Research site 03

Jorge Vinagre

Role: PRINCIPAL_INVESTIGATOR

Research site 04

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Almada, , Portugal

Site Status

Research Site

Espinho, , Portugal

Site Status

Research Site

Loures, , Portugal

Site Status

Research Site

Oeiras, , Portugal

Site Status

Research Site

Santo Antonio Dos Cavaleiros, , Portugal

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Portugal

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CV/No drug/NIS-CPO-XXX-2012/1

Identifier Type: OTHER

Identifier Source: secondary_id

NIS-CPO-XXX-2012/1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.